RNS Number : 6177A
Genedrive PLC
15 August 2024

genedrive plc
("genedrive" or the "Company")

Director/PDMR Notification

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, makes the following announcement regarding a transaction in the Company's ordinary shares by Dr Ian Gilham, Non-Executive Chairman.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

<table>
<tr><td>1.</td><td colspan="2">Details of the person discharging managerial responsibilities / person closely associated</td></tr>
<tr><td>a.</td><td>Name</td><td>Dr Ian Gilham</td></tr>
<tr><td>2.</td><td colspan="2">Reason for the notification</td></tr>
<tr><td>a.</td><td>Position/status</td><td>Non-Executive Chairman</td></tr>
<tr><td>b.</td><td>Initial notification /Amendment</td><td>Initial</td></tr>
<tr><td>3.</td><td colspan="2">Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</td></tr>
<tr><td>a.</td><td>Name</td><td>genedrive plc</td></tr>
<tr><td>b.</td><td>LEI</td><td>213800ZYODIRZ87Y4K14</td></tr>
<tr><td>4.</td><td colspan="2">Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</td></tr>
<tr><td>a.</td><td>Description of the Financial instrument, type of instrument Identification code</td><td>Ordinary Shares of 1.5p each

GB00B1VKB244</td></tr>
<tr><td>b.</td><td>Nature of the transaction</td><td>Purchase of ordinary shares</td></tr>
<tr><td>c.</td><td>Price(s) and volume(s)</td><td><table><tr><th>Price(s)</th><th>Volume(s)</th></tr><tr><td>3.1p</td><td>1,000,000</td></tr></table></td></tr>
<tr><td>d.</td><td>Aggregated information
· Aggregated volume
· Price</td><td>1,000,000 Ordinary Shares
3.1p per Ordinary Share</td></tr>
</table>

e.	Date of the transaction	14 August 2024
f.	Place of the transaction	London Stock Exchange, AIM Market (XLON)

For further details please contact:

genedrive plc +44 (0)161 989 0245
Gino Miele: CEO / Russ Shaw: CFO

Peel Hunt LLP (Nominated Adviser and Broker) +44 (0)20 7418 8900
James Steel / Patrick Birkholm

Walbrook PR Ltd (Media & Investor Relations) +44 (0)20 7933 8780
Anna Dunphy or genedrive@walbrookpr.com
+44 (0)7876 741 001

About genedrive plc(http://www.genedriveplc.com)

genedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. This helps clinicians to quickly access key genetic information that will aid them make the right choices over the right medicine or dosage to use for an effective treatment, particularly important in time-critical emergency care healthcare paradigms. Based in the UK, the Company is at the forefront of Point of Care pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on how your individual genetics impact a medicines ability to work for you. Therefore, by using pharmacogenetics, medicine choices can be personalised, made safer and more effective. The Company has launched its two flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, both developed and validated in collaboration with NHS partners and deployed on its point of care thermocycler platform. Both tests are single-use disposable cartridges which are ambient temperature stable, circumventing the requirement for cold chain logistics. The Directors believe the Genedrive® MT-RNR1 ID Kit is a worlds-first and allows clinicians to make a decision on antibiotic use in neonatal intensive care units within 26 minutes, ensuring vital care is delivered, avoiding adverse effects potentially otherwise encountered and with no negative impact on the patient care pathway. Its CYP2C19 ID Kit which has no comparably positioned competitor currently allows clinicians to make a decision on the use of Clopidogrel in stroke patients in 70 minutes, ensuring that patients who are unlikely to benefit from or suffer adverse effects from Clopidogrel receive an alternative antiplatelet therapeutic in a timely manner, ultimately improving outcomes. Both tests have undergone review by the National Institute for Health and Care Clinical Excellence ("NICE") and have been recommended for use in the UK NHS. The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester.

The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHEANPSFDXLEEA